Charles River Laboratories International, Inc.
Location
Massachusetts
Founded
1947-02-28
Website
Risk Signals
1057 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research, Testing Laboratories), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Charles River Laboratories International, Inc.
Live alerts from global media, monitored by Business Radar
2025-03-31 (taiwannews.com.tw)
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update | Taiwan News | Apr. 1, 2025 04:25
Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing
Read more
2025-02-19 (tradingview.com)
Charles River Laboratories Reports Q4 and Full-Year 2024 Results — News
Charles River Laboratories International, Inc. has released its financial results for the fourth quarter and full-year 2024, along with its guidance for 2025. The company, which provides essential products and services to pharmaceutical and biotechnology companies, reported a mixed performance with…
Read more
2025-02-19 (stocktitan.net)
Charles River Labs Posts Q4 Loss on $215M Impairment, Forecasts 2025 Revenue Decline | CRL Stock News
CRL reports Q4 revenue of $1B amid biotech spending constraints. Plans $350M stock buyback for 2025 despite projecting 3.5-5.5% organic revenue decline.
Read more
2025-02-19 (nasdaq.com)
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall |
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
Read more
2025-02-14 (kingsresearch.com)
Pharmaceutical tests Subsourcing market size, participation, growth and industry analysis, by product type (small molecule medications, biological products, medical devices), by type of service (bioanalytic tests, method development and validation, test stability, raw material tests, others), others), by end user and regional analysis, 2024-2031
It is projected that the Pharmaceutical Analytical Tests Subcontracting Market will reach $ 4,677.4 million by 2031 of $ 2,809.9 million in 2024, exhibiting an annual compound rate of 7.55%.
Read more
2025-02-11 (etfdailynews.com)
Charles River Laboratories International (CRL) Projected to Post Quarterly Earnings on Wednesday -
Read Charles River Laboratories International (CRL) Projected to Post Quarterly Earnings on Wednesday at ETF Daily News
Read more
2025-01-28 (businesswire.com)
Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call | Business Wire
Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call
Read more
2025-01-27 (nature.com)
The role of homogenization cycles and Poloxamer 188 on the quality of mitochondria isolated for use in mitochondrial transplantation therapy | Scientific Reports
Scientific Reports - The role of homogenization cycles and Poloxamer 188 on the quality of mitochondria isolated for use in mitochondrial transplantation therapy
Read more![Cell Therapy Market Report [2031] – Size, Share, Growth](https://images.businessradar.com/articles/6f706a26-d7a5-48f2-9a3d-88c508c13135)
2025-01-25 (kingsresearch.com)
Cell Therapy Market Report [2031] – Size, Share, Growth
The scale of the cell therapy market is expected to increase from US $ 10.84 billion in 2024 to US $ 26.59 billion in 2031, with a compound annual growth rate of 13.67%.
Read more